Global Payments has spent this week caught between a short position that continues to unwind and an analyst community that still can't stop trimming its targets.
Short interest has fallen another 14% over the past week to 5.9% of the float — continuing the retreat flagged in the previous note, where SI had already dropped sharply from a mid-May peak near 7.5% of float. That prior peak came in around May 8, when roughly 19.5 million shares were short; the position has since been reduced by nearly 6 million shares. This is meaningful covering, not noise. Yet it hasn't translated into price conviction: GPN closed at $74.03, up just 1% on the week after giving back nearly 2% on Tuesday alone. The borrow market remains entirely unstressed — availability has loosened further to 654%, compared with 563% just a week ago, and cost to borrow is essentially flat at 0.55%. There is no squeeze dynamic here; shorts are leaving by choice, not under pressure.
Options positioning has also calmed since last week's more defensive read. The put/call ratio is now 0.52, near the 20-day mean of 0.50 and only 0.6 standard deviations above it — a long way from the 2.1 z-score that made the prior note's hedging story so striking. That earlier caution has faded. The 52-week PCR range runs from 0.39 to 2.28, which puts the current reading squarely in the middle — neither bullish nor defensive. Options traders, in short, have moved to the sidelines.
The analyst picture is where the pressure continues to accumulate. Susquehanna's James Friedman lowered his target to $111 from $119 today while maintaining a Positive rating — the most recent in a long line of cuts. Since early April, every action has been a trim: RBC cut to $82, Citigroup to $90, Truist to $76 twice, Cantor Fitzgerald to $76, Stephens to $80, and now Susquehanna. BMO initiated at Market Perform with a $76 target in late April. The mean target across the Street is $94.62, which implies roughly 28% upside to the current $74 price — but that gap reflects how far the stock has fallen rather than how much the Street believes in the recovery. Raymond James downgraded to Market Perform in late March. The collective direction is clear: analysts are not cutting their ratings en masse, but they are steadily moving their targets closer to where the stock already trades. The bulls point to H2 revenue tailwinds, easing renewal cycles, and potential $200 million in EvoSynergies revenue. Bears counter that 1% net revenue growth, FX drag, and integration risks leave little room for error.
The ORTEX short score has drifted lower this week to 47.1, down from 51.3 on May 26 — a notable moderation that aligns with the covering activity. The EPS 12-month forward year-on-year increase factor ranks in the 86th percentile, suggesting the forward earnings trajectory looks better than the current price implies. The EPS momentum factors over 30 and 90 days also score above 50. But the EPS surprise factor sits at just the 2nd percentile — meaning the company has not been beating estimates — and the Altman Z-score of 0.84, flagged in the recent stock-score note, remains a concern on financial resilience.
On the institutional side, GTCR LLC remains the dominant holder with 15.8% of shares — a position that gives the stock a concentrated ownership profile unusual for a name this size. Citadel added nearly 3.8 million shares in Q1 2026, bringing its position to 1.9% of the company. Among the recent insiders trades, CEO Cameron Bready sold 2,297 shares on June 1 at $75.46, as did General Counsel Dara Steele-Belkin. Both transactions are modest and scored low on significance — they appear routine rather than directional. The 90-day net insider position is marginally positive at around 4,600 net shares, entirely reflecting the February award activity rather than open-market buying.
The next earnings event is scheduled for August 6. That gives the story a two-month window, and the key question heading into that print is whether management can demonstrate that the H2 revenue recovery is tracking — and whether the EvoSynergies contribution is on schedule. Peers had a rougher Tuesday: PAY fell nearly 8% on the day and MQ dropped 5.7%, while GPN held up relatively better at -1.9%. The week's covering activity has reduced short positioning to near its lowest level in six weeks, but with no borrow squeeze and a still-skeptical analyst community, the path higher depends on fundamentals, not positioning mechanics.
See the live data behind this article on ORTEX.
Open GPN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
